1 active not recruiting, 1 completed. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow PDS0101: new trials by email Literature Review of PDS0101 trials Research Report on PDS0101
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 20 | 2022-06-16 | 2026-10-07 |
| Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies PDS0101, M7824, NHS-IL12 - Cervical Cancer, HPV Cancers | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 51 | 2020-06-09 | 2026-06-30 |
Oropharyngeal Neoplasms (2) · Anus Neoplasms (1) · Carcinoma (1) · Rectal Neoplasms (1) · Uterine Cervical Neoplasms (1)
Mayo Clinic (1) · National Cancer Institute (NCI) (1)
United States (2)
Charalampos Floudas, M.D. (1) · David M. Routman, M.D. (1)